Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $3.93 Consensus Price Target from Brokerages

by · The Cerbat Gem

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned a consensus rating of “Reduce” from the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $3.9286.

A number of equities analysts recently weighed in on the company. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Pliant Therapeutics in a research note on Friday, October 10th. Wall Street Zen upgraded shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Wednesday, October 8th.

View Our Latest Stock Analysis on PLRX

Pliant Therapeutics Price Performance

Shares of NASDAQ:PLRX opened at $1.35 on Monday. The company has a market capitalization of $82.96 million, a PE ratio of -0.47 and a beta of 1.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.93 and a current ratio of 13.94. The stock has a fifty day moving average of $1.43 and a 200-day moving average of $1.49. Pliant Therapeutics has a one year low of $1.10 and a one year high of $13.27.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.10. As a group, equities analysts anticipate that Pliant Therapeutics will post -3.64 EPS for the current fiscal year.

Institutional Trading of Pliant Therapeutics

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in shares of Pliant Therapeutics in the first quarter worth $1,642,000. Peapod Lane Capital LLC raised its position in Pliant Therapeutics by 39.2% during the second quarter. Peapod Lane Capital LLC now owns 893,730 shares of the company’s stock valued at $1,037,000 after buying an additional 251,537 shares during the period. Monaco Asset Management SAM purchased a new stake in Pliant Therapeutics in the 2nd quarter worth about $815,000. Goldman Sachs Group Inc. boosted its position in Pliant Therapeutics by 6.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company’s stock worth $642,000 after acquiring an additional 29,177 shares during the period. Finally, Voleon Capital Management LP purchased a new position in Pliant Therapeutics during the 1st quarter valued at about $97,000. 97.30% of the stock is owned by institutional investors and hedge funds.

Pliant Therapeutics Company Profile

(Get Free Report)

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

See Also